Business Wire

Speech Processing Solutions Launches Philips SpeechLive Health, an AI Assistant Built for Modern Clinical Documentation

17.3.2026 15:00:00 CET | Business Wire | Press release

Share

Philips SpeechLive Health AI Assistant uses healthcare-trained AI to convert clinical conversations into structured notes, helping clinicians reduce administrative burden

Speech Processing Solutions, the global leader in professional dictation and speech solutions sold under the Philips brand, today announced the upcoming April 2026 launch of Philips SpeechLive Health AI Assistant, an AI-powered clinical documentation assistant designed for healthcare professionals across multiple care settings. This solution reduces administrative burden, streamlines documentation, and improves provider and patient experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317743584/en/

Philips SpeechLive Health AI Assistant turns clinical conversations into structured documentation, helping reduce administrative workload and create more time for patient care.

Purpose-built for clinical documentation workflows

Clinical workload remains a major challenge across healthcare. In the U.S., AMIA’s 2024 TrendBurden survey found that 77% of healthcare professionals said documentation makes them work late or at home, while 74% said documentation impedes patient care1. In Europe, health systems are also under strain, with shortages of around 1.2 million doctors, nurses and midwives in the EU2. Philips SpeechLive Health AI Assistant is designed to address these pressures by reducing documentation effort, streamlining routine workflows, and enabling clinicians to spend more time on patient care.

SpeechLive Health captures clinical conversations in real time and converts them into structured documentation, including SOAP notes, visit summaries, and referral letters. By supporting clinicians during consultations, the solution helps streamline documentation while maintaining the accuracy and structure required for clinical records.

Unlike general-purpose AI models, SpeechLive Health uses a healthcare-trained large language model built by doctors specifically for medical environments. Built for clinical use, the system generates structured documentation that supports clinical workflows, coding and compliance requirements.

“For more than 70 years, Speech Processing Solutions has helped shape professional dictation and transcription in healthcare and has established a reputation as a leading partner in the medical market,” said Dr. Thomas Brauner, CEO of Speech Processing Solutions. “Philips SpeechLive Health marks the next step in that journey – building on the strong foundation of superior dictation hardware and leading software solutions combined. By adding this healthcare-trained AI assistant, we’re creating the next generation of an integrated solution that further reduces administrative burden, simplifies workflows and multiplies customer benefits, giving clinicians more time for patient care.”

AI designed for accuracy, compliance, and clinical trust

SpeechLive Health enables real-time documentation during visits, reducing the need for manual note-taking. In high-volume or conversation-heavy settings, the AI assistant reduces the time clinicians spend on documentation, allowing practitioners to stay present with their patients.

Built in line with SPS’s privacy-first strategy, SpeechLive Health has security and compliance at its core. The platform supports AES-256 encryption and aligns with major healthcare and data protection frameworks, including HIPAA and GDPR, while meeting internationally recognized standards such as ISO 27001. Clinicians retain control over stored audio files and editable documentation within the system.

Integrated software and hardware for clinical documentation

SpeechLive Health, used together with the new Philips SpeechMike Ambient Wearable AI Assistant for clinical environments, delivers the high level of audio capture quality required for successful clinical documentation. With a multi-microphone array and AI-based voice-filtering technology, the hands-free device captures clear speech from speakers and doctor-patient conversations, even in busy healthcare settings.

This supports accurate real-time documentation by complementing the SpeechLive Health platform, forming an end-to-end integrated solution designed to simplify clinical documentation workflows while maintaining the reliability and security required in healthcare.

Philips SpeechLive Health AI Assistant will be available starting in April 2026 through the global SpeechLive sales partner network.

Speech Processing Solutions (SPS):

Speech Processing Solutions (SPS) is the global leader in professional dictation and speech AI solutions, serving more than 4 million users in over 50 countries through a worldwide network of more than 1,000 partners. The company develops and markets industry-leading dictation and transcription solutions, documentation workflows powered by speech recognition, and award-winning dictation devices under the Philips brand. SPS’s mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.

1https://amia.org/news-publications/amia-survey-underscores-impact-excessive-documentation-burden

2https://www.oecd.org/en/publications/health-at-a-glance-europe-2024_b3704e14-en/full-report.html

View source version on businesswire.com: https://www.businesswire.com/news/home/20260317743584/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye